Effect of Nocturnal Parenteral Nutrition on Bone Turnover and Energy Metabolism (NutriSync)

October 20, 2023 updated by: Prof. Dr. Mireille JM Serlie, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

The Effect of Parenteral Nutrition During Nighttime Versus Daytime on Bone Turnover and Energy Metabolism in Intestinal Failure Patients

This clinical trial will study the effect of daytime versus nighttime parenteral nutrition on bone turnover, glucose variability, nitrogen balance, sleep and wake rhythm and peripheral clock gene expression in patients with chronic intestinal failure.

Study Overview

Detailed Description

Objective: This randomized crossover pilot study aims to determine the effect of nocturnal versus daytime cyclic infusion of parenteral nutrition in adult patients with chronic intestinal failure on bone turnover, glucose metabolism, nitrogen balance, sleep and wake rhythm and clock genes expression.

This study will include 20 adult patients with chronic intestinal failure. Patients will receive nocturnal parenteral nutrition for 2 weeks (period A) and will switch to daytime parenteral nutrition (period B) for 2 weeks (random assignment). During both study periods glucose variability and sleep / wake rhythm will be measured. After both study periods, patients will be admitted to the metabolic unit for 24 hours to measure bone turnover markers, nitrogen balance, glucoregulatory hormones, energy expenditure and substrate oxidation rates and clock gene expression in leukocytes.

Study Type

Interventional

Enrollment (Estimated)

20

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Home parenteral nutrition for at least 5 nights a week
  • On home parenteral nutrition for more than 1 year
  • No major changes in parenteral nutrition for 3 months prior to inclusion

Exclusion Criteria:

  • Parenteral infusion for more than 16 h a day
  • Use of bone modifying drugs in the last 2 years
  • Bone fractures in the past year
  • Renal insufficiency (eGFR < 60 ml/min)
  • HbA1c ≥48 mmol/ml
  • Use of corticosteroids
  • Shift work
  • Performing intensive exercise (> 2 hours a day and > 3 times a week)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Nocturnal parenteral nutrition
Patients will receive nocturnal parenteral nutrition, starting at 8pm
Parenteral nutrition will be administered starting at 8 pm
Other Names:
  • active comparator
Parenteral nutrition will be administered starting at 8 am
Other Names:
  • experimental
Experimental: Diurnal parenteral nutrition
Patients will receive diurnal parenteral nutrition, starting at 8am
Parenteral nutrition will be administered starting at 8 pm
Other Names:
  • active comparator
Parenteral nutrition will be administered starting at 8 am
Other Names:
  • experimental

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differences in bone turnover marker Procollagen 1 Intact N-Terminal Propeptide
Time Frame: Study day 1 versus study day 2
Differences in the bone turnover marker Procollagen 1 Intact N-Terminal Propeptide (ug/L)
Study day 1 versus study day 2
Differences in bone turnover marker carboxy-terminal collagen crosslinks
Time Frame: Study day 1 versus study day 2
Differences in bone turnover marker carboxy-terminal collagen crosslinks (ng/L)
Study day 1 versus study day 2
Changes in glucose variability
Time Frame: 2 weeks versus 2 weeks
Changes in glucose variability measured by a continuous glucose monitor
2 weeks versus 2 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in plasma insulin
Time Frame: Study day 1 versus study day 2
insulin (pmol/L)
Study day 1 versus study day 2
Changes in plasma glucagon
Time Frame: Study day 1 versus study day 2
glucagon (ng/L)
Study day 1 versus study day 2
Changes in nitrogen balance
Time Frame: Study day 1 versus study day 2
Changes in nitrogen balance by comparing output (feces/urine) versus intake (oral/enteral/parenteral)
Study day 1 versus study day 2
Changes in sleep/wake rhythm
Time Frame: 2 weeks versus 2 weeks
Changes in sleep/wake rhythm measured by an actigraph
2 weeks versus 2 weeks
Changes in clock gene expression
Time Frame: Study day 1 versus study day 2
Changes in clock gene expression in leukocytes (if feasible; pilot)
Study day 1 versus study day 2
Changes in energy expenditure
Time Frame: Study day 1 versus study day 2
Changes in energy expenditure assessed by indirect calorimetry (kcal/24h)
Study day 1 versus study day 2
Changes in sleep quality
Time Frame: 2 weeks versus 2 weeks
Changes in sleep quality, measured by Visual Analogue Scale (VAS) score (scale 1-10, higher scores mean better outcome)
2 weeks versus 2 weeks
Changes in substrate oxidation rates
Time Frame: Study day 1 versus study day 2
Changes in substrate oxidation rates assessed by indirect calorimetry (percent)
Study day 1 versus study day 2

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in body temperature
Time Frame: Study day 1 versus study day 2
Changes in body temperature measured by i-buttons (Celsius)
Study day 1 versus study day 2

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: G.M. vd Werf, MSc, RD, Amsterdam UMC, location AMC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 13, 2023

Primary Completion (Estimated)

November 1, 2024

Study Completion (Estimated)

November 1, 2025

Study Registration Dates

First Submitted

April 21, 2023

First Submitted That Met QC Criteria

May 11, 2023

First Posted (Actual)

May 22, 2023

Study Record Updates

Last Update Posted (Actual)

October 23, 2023

Last Update Submitted That Met QC Criteria

October 20, 2023

Last Verified

October 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Non-identifiable data will be available after signing a data sharing agreement with the legal support office of the Amsterdam University Medical Center

IPD Sharing Time Frame

After publication of the study results and for a period of 15 years

IPD Sharing Access Criteria

Data sharing agreement with legal support office

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe